Tau PET Outcomes With Anti-amyloid Immunotherapies

Launched by MAYO CLINIC · Dec 5, 2024

Keywords

ClinConnect Summary

This clinical trial, called "Tau PET Outcomes with Anti-amyloid Immunotherapies," is looking to see how a specific type of brain scan, called a tau PET scan, changes in patients who are receiving new treatments for Alzheimer’s disease. The goal is to understand whether these treatments, which target amyloid proteins in the brain, help improve or stabilize cognitive function in people with mild cognitive impairment or mild Alzheimer’s disease.

To participate in this study, you need to be between 50 and 90 years old and have mild cognitive impairment or mild Alzheimer's disease, confirmed by a special test showing amyloid presence in your brain. If you qualify, you will undergo some brain scans and receive the anti-amyloid treatment. It's important to note that participants need to be able to lie still for about 10 minutes during the scans and cannot be pregnant or breastfeeding. This is an exciting opportunity to contribute to research that could help improve treatments for Alzheimer’s disease.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• • Age 50-90 years
• • Male or female
• • Mild cognitive impairment due to AD or mild AD
• • Amyloid positive via CSF or PET
• • Meets other eligibility criteria for anti-amyloid immunotherapy
• • Subject or delegate provides informed consent
• • Exclusion Criteria
• • Subjects unable to lie down without moving for 10 minutes.
• • Women who are pregnant or cannot stop breast feeding for 24 hours.
• • Claustrophobic patients unable to tolerate the scans (no sedation can be offered).